Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …

TM Maher, EM van der Aar, O Van de Steen… - The Lancet …, 2018 - thelancet.com
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …
被引用次数：245 相关文章

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …

TM Maher, EM van der Aar… - The Lancet …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …

TM Maher, EM van der Aar, O Van de Steen… - The Lancet …, 2018 - europepmc.org
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …

TM Maher, EM van der Aar, O Van de Steen… - The Lancet Respiratory …, 2018 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …

[引用][C] Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase …

TM Maher, EM van der Aar, O Van de Steen… - The Lancet Respiratory …, 2018 - cir.nii.ac.jp
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin
inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised …